

Example of a genetic for North of England

Liquid biopsy report

Genomic Signatures

Blood Tumor Mutational Burden - 9 Muts/Mb
ctDNA Tumor Fraction - Low (< 1.0%)
Microsatellite status - MSI-High Not Detected

Gene Alterations

For a complete list of the genes assayed, please refer to the Appendix.

AKT1 E17K
BRCA2 C3233fs*16
BAP1 M1V
CHEK2 R346G
DNMT3A splice site 855+1G>A
IKZF1 L376fs*39

This assay tested >300 cancer-related genes, including the following 7 gene(s) routinely assessed in this tumor type: **AKT1, BRCA1, BRCA2, ERBB2, ESR1, PIK3CA, PTEN.**


Report Highlights

- Targeted therapies with **NCCN categories of evidence** for genomic findings in this patient's tumor type: **Capivasertib + Fulvestrant** (p. 12), **Olaparib** (p. 13), **Talazoparib** (p. 14)
- Low ctDNA Tumor Fraction** was detected; in the absence of actionable driver alterations consider reflex testing to a regulated tissue test, such as FoundationOne®CDx (p. 6)
- Variants that may inform **nontargeted treatment approaches** (e.g., chemotherapy) in this tumor type: **BRCA2 C3233fs*16** (p. 8)
- Clinical trial options** based on this patient's genomic findings: (p. 16)
- Variants that may represent **clonal hematopoiesis** and may originate from non-tumor sources: **CHEK2 R346G** (p. 10), **DNMT3A** splice site 855+1G>A (p. 11)

GENOMIC SIGNATURES	
Blood Tumor Mutational Burden - 9 Muts/Mb	
ctDNA Tumor Fraction - Low (< 1.0%)	
Microsatellite status - MSI-High Not Detected	
GENE ALTERATIONS	VAF%
AKT1 - E17K 10 Trials see p. 16	0.23%
BRCA2 - C3233fs*16 10 Trials see p. 20	50.1%

THERAPY AND CLINICAL TRIAL IMPLICATIONS	
No therapies or clinical trials. See Genomic Signatures section	
Low ctDNA Tumor Fraction. This result does not compromise confidence in any reported alterations. See Genomic Signatures Finding Summary.	
MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).	
THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
Capivasertib + Fulvestrant <input type="checkbox"/>	None
Olaparib <input type="checkbox"/>	Niraparib
Talazoparib <input type="checkbox"/>	Rucaparib

NCCN category for genomic findings in patient's tumor type



HISTORIC PATIENT FINDINGS (Genomic Signatures)	ORD-2140884-01
Blood Tumor Mutational Burden	9 Muts/Mb
Microsatellite status	MSI-High Not Detected
ctDNA Tumor Fraction	< 1.0%
HISTORIC PATIENT FINDINGS (Gene Alterations)	VAF%
AKT1 ● E17K	0.23%
BRCA2 ● C3233fs*16	50.1%
BAP1 ● M1V	51.1%
CHEK2 ● R346G	0.50%
DNMT3A ● splice site 855+1G>A	0.47%
IKZF1 ● L376fs*39	0.22%

IMPORTANT NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne® Liquid CDx or FoundationOne® CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. Variants reported for prior time points reflect reporting practices at the time of the historical test(s). Changes in variant reporting nomenclature, classification, or handling may result in the appearance of discrepancies across time points. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

ctDNA Tumor Fraction may include previous Tumor Fraction results which reflect reporting practices at the time of reporting. Changes in biomarker reporting may result in the appearance of discrepancies across time points.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable or reportable variants may become VUS.